By proceeding, you agree to our Terms of Use and Privacy Policy.
Leads the CMC Development Department at Alnylam Pharmaceuticals and is responsible for the development and implementation of the CMC strategy for siRNA therapeutics, including delivery solutions like conjugates (GalNAc and others) and lipid nanoparti
Talks About #cmcdevelopment #biotechnology #drugdiscovery
Preferred Locations #NorthAmerica
Accelerate Novel Lipid Discovery, Optimized Formulation & Tightened CQAs for Process Development to Achieve Scalability & Regulatory Compliance for Improved Product Quality & Widened Therapeutic Windows.
